Details of the Drug Formulations

General Information of Drug (ID: DMC7W6R)

Drug Name
Selumetinib Drug Info
Synonyms
Selumetinib; AZD-6244; ARRY142886; AZD6244; ARRY142886; AZD 6244; AZD-6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Thyroid cancer 2D10 Phase 3 [2]
Non-small-cell lung cancer 2C25.Y Phase 2 [3] , [4]
Solid tumour/cancer 2A00-2F9Z Investigative [5]
Cross-matching ID
PubChem CID
10127622
ChEBI ID
CHEBI:90227
CAS Number
606143-52-6
TTD ID
D0T5DP
ACDINA ID
D01422

Full List of Drug Formulations Containing This Drug

Selumetinib 25 mg capsule
Company Formulation ID FDA Description
Astrazeneca Pharmaceuticals F23892 Vitamin E Polyethylene Glycol Succinate; Hypromellose; Carrageenan; Potassium Chloride; Titanium Dioxide; Fd&C Blue 2; Ferric Oxide Yellow; Purified Water; Carnauba Wax; Corn Starch; Ferric Oxide Red; Ferric Oxide Yellow; Fd&C Blue 2 Aluminum Lake; Carnauba Wax; Shellac; Glyceryl Monooleate
------------------------------------------------------------------------------------
Selumetinib 10 mg capsule
Company Formulation ID FDA Description
Astrazeneca Pharmaceuticals F23891 Vitamin E Polyethylene Glycol Succinate; Hypromellose; Carrageenan; Potassium Chloride; Titanium Dioxide; Carnauba Wax; Purified Water; Shellac; Iron Oxide Black; Propylene Glycol; Ammonium Hydroxide
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01933932) Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5665).
4 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).